In collaboration with the European Investment Bank (EIB), the Health Emergency Preparedness and Response Authority (HERA) has committed €20 million to support the French biopharmaceutical company Fabentech in developing and deploying broad-spectrum therapeutics aimed at combating biological threats to public health.
HERA’s threat analysis has underscored the critical importance of Fabentech’s innovative technology platform, which produces broad-spectrum polyclonal antibody fragments that neutralise pathogens and toxins within the human body. This advancement is expected to play a crucial role in strengthening Europe’s ability to respond swiftly to public health emergencies.
The agreement with Fabentech is the first of many expected investments under the HERA Invest initiative, which aims to drive innovation to tackle key health threats. These include pathogens with pandemic potential, chemical, biological, radiological, and nuclear (CBRN) threats, as well as the growing issue of antibiotic resistance. More investments with other European companies are anticipated, stimulating Europe’s preparedness and ability to manage future crises.
More info here